Discontinued — last reported Q4 '20
Current Assets
Available-for-Sale Debt Securities - Amortized Cost
Pfizer Available-for-Sale Debt Securities - Amortized Cost increased by 12.5% to $11.56B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 50.5%, from $7.68B to $11.56B. Over 4 years (FY 2020 to FY 2024), Available-for-Sale Debt Securities - Amortized Cost shows an upward trend with a 4.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2020
How to read this metric
An increase reflects new debt security purchases, while a decrease indicates maturities or sales of existing holdings.
Detailed definition
This represents the original cost of debt securities classified as available-for-sale, adjusted for amortization of prem...
Peer comparison
Standard accounting metric; allows for comparison of investment cost bases across financial institutions.
Metric ID:
afs_debt_securities_amortized_costHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.62B | $26.46B | $24.84B | $19.89B | $28.18B | $24.59B | $21.56B | $17.63B | $25.55B | $28.65B | $5.13B | $9.23B | $5.52B | $7.68B | $11.94B | $14.94B | $10.28B | $11.56B |
| QoQ Change | — | +50.2% | -6.2% | -19.9% | +41.7% | -12.7% | -12.3% | -18.2% | +44.9% | +12.1% | -82.1% | +80.1% | -40.3% | +39.2% | +55.5% | +25.2% | -31.2% | +12.5% |
| YoY Change | — | — | — | — | +59.9% | -7.1% | -13.2% | -11.3% | -9.3% | +16.5% | -76.2% | -47.6% | -78.4% | -73.2% | +132.8% | +61.8% | +86.3% | +50.5% |
Range$5.13B – $28.65B
CAGR-9.4%
Avg YoY Growth+6.5%
Median YoY Growth-8.2%
Available-for-Sale Debt Securities - Amortized Cost at Other Companies
Frequently Asked Questions
- What is Pfizer's available-for-sale debt securities - amortized cost?
- Pfizer (PFE) reported available-for-sale debt securities - amortized cost of $11.56B in Q3 2025.
- How has Pfizer's available-for-sale debt securities - amortized cost changed year-over-year?
- Pfizer's available-for-sale debt securities - amortized cost increased by 50.5% year-over-year, from $7.68B to $11.56B.
- What is the long-term trend for Pfizer's available-for-sale debt securities - amortized cost?
- Over 4 years (2020 to 2024), Pfizer's available-for-sale debt securities - amortized cost has grown at a 4.5% compound annual growth rate (CAGR), from $9.99B to $11.94B.
- What does available-for-sale debt securities - amortized cost mean?
- The original purchase price of debt investments, adjusted for accounting adjustments, excluding current market price changes.